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Development of a new HPLC method for wogonin in rat plasma:
Compatibility of standard and test samples
In the current paper, an HPLC/UV method was developed 
and validated for determination of wogonin in plasma. 
Considerable att ention was paid to the preparation of stan-
dard samples and factors aff ecting drug distribution. A 
preparation procedure was devised to simulate the condi-
tions the drug is expected to experience in vivo while point-
ing to the shortcomings of previously published methods. 
The method was validated according to the FDA regula-
tions and showed to be highly effi  cient and capable of ex-
tracting the drug and IS from the plasma accurately and 
precisely within the specifi ed range of 50–500 ng mL–1. Fur-
ther, the standard sample preparation of this method can 
be used as a guideline for other methods, particularly 
when highly hydrophobic drugs with considerable protein 
binding are involved and could be valuable in the fi eld of 
bioanalysis to improve the reliability of methods.
Keywords: wogonin, HPLC/UV, standard sample prepara-
tion, sample compatibility
Knowledge of pharmacologically active species levels in body fl uids such as plasma 
and urine enables researchers to optimize their therapeutic eff ects (1). Biological fl uids and 
numerous pharmaceutical products are quite complex. Despite the development of highly 
effi  cient instruments for analysis, sample preparation (which may take 80 % of analysis 
time) is still crucial in order to extract and isolate the analytes of interest from such com-
plex media reliably (2). Sample preparation includes test and standard samples where the 
former requires extraction of a certain analyte from the matrix, while the latt er is mainly 
concerned with spiking specifi ed amounts of the analyte in the matrix of interest, followed 
by extraction. Compatibility of standard samples is essential because any defects in these 
samples can aff ect the reliability of the method; however, this particular issue does not 
receive adequate att ention from researchers and oft en stays away from the limelight. Stan-
dard samples are usually prepared in vitro, which explains the challenges of mimicking 
the complicated processes that test samples are confronting in vivo. Knowledge about the 
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physicochemical properties of the drug must be utilized for optimizing all the phases of 
bioanalytical methodology, such as spiking, extraction, separation and detection to maxi-
mize the chances of eff ective outcomes (3). During pharmaceutical formulation, some 
manufacturing processes may change the physical form of the drug. In such cases, it is 
diffi  cult to validate the accuracy of the method using spiked original analytes, since the 
recovery of the drug from these standard samples may not represent the recovery from a 
manufactured product (4). Further, plasma can aff ect drug distribution in vivo and can 
even prevent its detection (5). Thus, when the preparation of standard samples does not 
simulate in vivo conditions, then the recovery of the drug from these standard samples will 
not represent the recovery from test plasma samples. Method development should con-
sider all the possible aff ecting variables to achieve optimum yields.
Wogonin, a monofl avonoid extracted from a number of plants, exhibits a wide range 
of pharmacologic and therapeutic eff ects, such as antioxidant, anti-infl ammatory, neuro-
protective, antiviral and antitumor eff ects (6). Bioanalysis of wogonin is essential for the 
evaluation of all pharmaceutical preparations intended for clinical use. Most of the previ-
ously described methods for the bioanalysis of wogonin were performed using devices 
such as LC-MS/MS (7–9) or HPLC/UV (10, 11). In contrast, the compatibility of standard 
samples with test samples was not suffi  ciently considered in these reports, which is against 
strict recommendations of the FDA guidelines for the development of bioanalytical meth-
ods. In the current investigation, we report a new, simple and robust HPLC/UV method 
for the determination of wogonin in plasma following FDA regulations and considering 
variables aff ecting the standard sample preparation in order to maintain maximum pos-
sible compatibility with the test plasma samples. 
EXPERIMENTAL
Preparation of standard stock solutions
Wogonin standard stock solution was prepared by precisely weighing 5 mg of wogonin, 
which was fi rst dissolved in 100 μL of DMSO (dimethyl sulfoxide), then diluted with metha-
nol to give the fi nal concentration of 50 μg mL–1. Then, a set of working standard solutions 
for spiking standard plasma samples were prepared by dilution with methanol. Apigenin 
standard stock solution was prepared following the same procedure as for wogonin.
UV-VIS spectrophotometric analysis and HPLC conditions 
Spectrophotometric analysis was performed using an Agilent-8453 (USA) UV-VIS 
spectrophotometer at 25 °C to compare the UV/VIS spectra of wogonin and the proposed 
internal standard solutions (apigenin, IS), and to set an appropriate wavelength for HPLC 
analysis. An HPLC system (Shimadzu LC-2010C, Japan) equipped with an auto sampler 
and a diode array detector was used. Chromatographic separation was performed on a 
Hedera ODS-2 column (4.6 mm in diameter and 250 mm length, 5 μm). Isocratic mobile 
phase was used in this method, as previously reported (16, 22–24). It is composed of 75 % 
of methanol and 25 % of ammonium acetate buff er (77 mg L–1, pH adjusted to 4 with acetic 
acid). Flow rate was 1 mL min–1, column temperature was set to 25 °C, injected volume was 
30 μL and detection wavelength was 277 nm. Chromatographic data was acquired and 
analysed using the Shimadzu LC solution soft ware package.
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In vitro wogonin aqueous solubility
Briefl y, an excess amount of wogonin was kept in PBS (phosphate buff er saline) at 
37 °C in a shaking water bath for 72 hours. The solution was then centrifuged and fi ltered 
through a 0.22-μm pore fi lter. Wogonin concentration was then determined by HPLC.
Animal experiments and blood collection
All animal experiments performed in this study were evaluated and approved by the 
Animal and Ethics Review Committ ee of Southeast University (Nanjing, Jiangsu, People’s 
Republic of China). Male Sprague-Dawley rats (body mass around 220 g) were monitored 
twice a day and had free access to regular feed and water. Test animals were deprived of 
food for at least 12 hours prior to the commencement of the experiment but were freely al-
lowed to drink water. Wogonin aqueous suspension, in a dose of 40 mg kg–1 body mass, was 
administered orally. Blood collection before and aft er the treatment was performed through 
orbital sinus venepuncture utilizing capillary tubes pre-treated with heparin. Around 
0.5 mL of blood was collected each time in small Eppendorf tubes, which were also pre-
treated with heparin to prevent coagulation. The collected blood was centrifuged for 
10 minutes at 10000 rpm; plasma was then separated and kept at –20 °C until further use.
Optimization of standard sample preparation
Experiments were performed trying to simulate in vivo conditions. Hence, in order to 
investigate the eff ects of spiking organic solvents on the in vivo-in vitro correlation, two 
groups of standard samples were prepared in duplicate, as illustrated in Fig. 1. For group 1, 
Fig. 1. Schematic presentation illustrating the standard preparation steps in preliminary experi-
ments.
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10 μL of wogonin working solution (0.5, 1.25, 2.5 μg mL–1) was directly spiked into 200 μL 
of blank plasma, vortexed and then 10 μL (30 μg mL–1) of IS stock solution was added. In 
group 2, 200 μL of blank plasma was fi rst added to the same solutions of wogonin but 
vortexed aft er evaporating the organic solvent and then moved to tubes that contained the 
same amount of IS aft er its organic solvent was evaporated. Both groups, 1 and 2, were 
vortexed before extraction and analysed by HPLC. Comparison of drug recovery of both 
sets was used to optimize the standard sample preparation conditions.
Extraction of wogonin and apigenin
Test plasma samples (from dosed animals) were fi rst added to the IS aft er evaporation 
of its organic solvent. The same steps of extraction were performed for both test and stan-
dard samples. It started by the addition of ethyl acetate to each sample and vortex for 5 
min. Centrifugation was then performed at 12,000 rpm for 5 min at 4 °C, the clear organic 
solution was transferred to a clean centrifuge tube and was evaporated to dryness under 
vacuum. The samples were fi nally reconstituted with 200 μL of methanol and analysed by 
HPLC aft er fi ltration through 0.22-μm fi lters.
Method validation
In the development phase, experimental conditions of extraction and HPLC proce-
dures (such as the mobile phase components ratio and pH, fl ow rate and column tempera-
ture) were tested to ensure the robustness of the method. The method was then validated 
according to the FDA guidelines (12).
Calibration curve and linearity. – The calibration curve was developed using a series of 
blank plasma samples (200 μL) spiked with increasing concentrations of wogonin and 
fi xed amounts of IS. The peak area ratio of wogonin to IS was plott ed against the concentra-
tion to get a standard calibration curve.
Selectivity. – Selectivity of wogonin detection in plasma was tested according to the 
FDA regulations (12) using drug free blank plasma, blank plasma spiked with wogonin 
and IS and plasma from wogonin-treated rats spiked with IS. All samples were prepared 
according to the fi nal optimized conditions and were extracted according to the same 
method.
Accuracy. – Five standard samples corresponding to each of the low, medium and high 
concentrations of wogonin were prepared and analysed by HPLC.
Precision. – To ensure precision, fi ve samples corresponding to each of the low, medium 
and high concentrations of wogonin were prepared according to the optimized method, 
analysed and the intra-day precision was recorded. Then, each concentration was prepared 
daily in a sample and analysed for fi ve consecutive days to calculate inter-day precision.
Extraction recovery. – Recovery experiments were performed by comparing the ana-
lytical results for extracted standard samples at three concentrations (low, medium, and 
high) with unextracted standards, representing 100 % recovery. Five samples of each (low, 
medium and high concentrations of wogonin) were spiked into blank plasma under opti-
mized conditions, extracted and compared with equivalent concentrations of pure wogo-
nin in methanol (without extraction) aft er HPLC analysis. The mean peak area of the ex-
tracted wogonin divided by the mean peak area of the non-extracted wogonin equals the 
absolute extraction recovery (n = 5).
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Limits of detection and quantitation. – Based on the standard deviation of the response 
and the slope, the limit of detection (LOD) and the limit of quantitation (LOQ) were esti-
mated using the following formula: LOD = 3.3 σ/S, LOQ = 10 σ/S, where σ is standard de-
viation of the response (standard deviation of y-intercepts of the regression line), S is the 
slope of the calibration curve.
RESULTS AND DISCUSSION
Optimization of the method
Prior to the commencement of HPLC experiments, standard solutions of wogonin and 
internal standard IS (apigenin) were analysed by UV-VIS spectrophotometry to identify the 
exact λmax. Results (Fig. 2b) showed a prominent peak of wogoninat 277 nm, which is very 
close to the peak of apigenin (IS) at 268 nm. As a result, 277 nm was set as the analysis λmax.
Selection of the internal standard
In the current experiment, we selected apigenin (4,5,7-trihydroxyfl avone), a fl avonoid 
having a very close structure to wogonin (Fig. 2a). Apigenin shows extremely low aqueous 
solubility, estimated to be around 5 μmol L–1and pKa value of 7.86 (13). These values are 
very close to those of wogonin, which has aqueous solubility of 2.34 μmol L–1 (14) and pKa 
value of 7.48 ± 0.1 (15). The two compounds are therefore expected to have a very low dis-
sociation capacity in aqueous media such as blood plasma. The similarity in these funda-
mental physicochemical properties makes their recovery from the plasma relatively simi-
lar, which makes apigenin a perfect choice for IS in this method. The other two compounds 
that were primarily considered for IS, since they possess peak UV absorbance very close 
to that of wogonin, were ibuprofen at 263 nm and diclofenac sodium at 275 nm. However, 
they were excluded later not only due to the obvious diff erence in structure or aqueous 
solubility but also because, in the current mobile phase, both compounds showed wide 
peaks that interfered with the peak of wogonin, aff ecting the method’s selectivity.
Fig. 2. Molecular structure and UV spectra of: a) apigenin (IS) and b) wogonin.
a)                                                                               b)
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Extraction of wogonin and apigenin
Wogonin and apigenin are expected to be retained in the organic phase (ethyl acetate); 
the optimized volume ratio ethyl acetate/plasma sample is 5:1. This is to overcome protein 
binding and recovering the protein bound fraction of the drug, namely, to ensure the 
quantitative isolation of wogonin and apigenin. 
Optimization of standard sample preparation
Three standard solutions of wogonin with concentrations of 0.5, 1.25 and 2.5 μg mL–1 
were primarily used to evaluate the signifi cance of involving an organic solvent in stan-
dard sample preparation and its eff ects on compatibility with the in vivo samples. The re-
sults showed recovery of more than 90 % for all concentrations of group 1, in which stan-
dard solutions (with organic solvent) were directly spiked into plasma samples. For group 
2, when plasma was added aft er evaporating the solvent from the standard solution, only 
the lowest concentration showed high recovery of more than 80 %, whereas the other two 
concentrations exhibited an extreme decline in recovery. As expected, the recovery was 
inversely proportional to the concentration, reaching only 27 % for the highest concentra-
tion of 2.5 μgmL–1. Therefore, the factors aff ecting wogonin distribution in plasma were 
re-assessed and considered to clarify these results and to optimize our method. Among 
these factors were wogonin aqueous solubility and its protein binding properties, which 
were thoroughly investigated along with other related factors.
Aqueous solubility of wogonin. – Wogonin solubility in PBS was found to be 2.77 μmol L–1, 
which is very close to the previously reported value for solubility in water of 2.34 μmol L–1 
(14). It is apparent that wogonin has an extremely low aqueous solubility profi le, which can 
explain the big diff erence in recovery of the two groups in preliminary experiments. In 
other words, the addition of drug dissolved in organic solvent disregarded the ability of 
the plasma to solubilize the drug independently. The drug was solubilized with the aid of 
the organic solvent and the extraction process cannot represent the extraction from pure 
plasma, unlike the case in vivo. Consequently, when organic solvents are involved, higher 
concentrations of wogonin, even more than the capacity of the plasma to solubilize, could 
be mistakenly used to develop the calibration curve. Hence, such standard samples lack 
compatibility with the test samples and they may lead to deceptive results and make the 
method validity questionable. Unfortunately, this was widely done in methods published 
earlier (10, 16–19). Such approaches are in contradiction with the recommendations of the 
FDA guidance for bioanalytical method validation, which state that the concentrations of 
standards should be chosen on the basis of the concentration range expected in a particu-
lar study (12). Accordingly, we concluded that a maximum concentration of 500 ng mL–1 
should be used in the preparation of standard samples to guarantee the ability of plasma 
to solubilize it freely. Also, the volumes of blank plasma used in standard samples were 
maintained to independently solubilize the analyte in the concentration range intended 
for developing the calibration curve.
Wogonin protein binding and plasma distribution
The calibration curve must be prepared in the same biological matrix as the samples 
in the planned study by spiking the matrix with known concentrations of the analyte (12). 
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Introduction of organic solvents during standard sample preparation will interrupt the 
composition of the blank plasma matrix, especially if considerable volumes relative to 
plasma are used. This action must be particularly avoided in order to maintain the compati-
bility between standard and test samples and the negative consequences for the plasma 
content and its relation with wogonin distributionare worth mentioning. Organic solvents, 
particularly methanol, have the ability to precipitate plasma proteins (20). When it is intro-
duced into standard samples, the drug protein-binding pathway will be aff ected and the 
drug will be easily recovered (by ethyl acetate) in the extraction process. This can further 
explain the high recovery of all concentrations of wogonin from group 1 and potentiates 
our hypothesis of such samples being incompatible with the test samples. Analysis of 
previous methods of wogonin quantitation in plasma showed that changing the plasma 
matrix with organic solvents was widely conducted during standard sample preparations 
(7, 8, 10, 16–19, 21). It was performed through direct spiking of the working standard stock 
solutions of wogonin (with organic solvents) in ratios ranging between 10–50 % of the 
blank plasma volume while ignoring the consequences for drug solubility and sample 
integrity and hence their validity. In the current method, in order to prevent such sce-
narios, the fi nal method protocol was designed to introduce wogonin and IS solely into 
blank plasma aft er evaporating the methanol content to preserve its matrix composition 
and hence compatibility with the test samples.
In the context of protein binding, some drugs and especially those with a high hydro-
phobic nature have high affi  nity to binding to plasma proteins by as much as 99 % or 
higher (5). In addition, covalent protein binding can signifi cantly aff ect analytical detecta-
bility of such pharmaceutical compounds. Although most of drug-protein binding in-
volves non-covalent hydrophobic forces, they are adequate to form a very tight bond to 
specifi c sites of some proteins (22). Temperature and time are among the main factors that 
aff ect the degree of wogonin protein binding, as previously reported (23–25). These re-
ports showed that the binding process was primarily exothermic, spontaneous, enthalpy 
and entropy driven. The major part of binding energy was electrostatic interaction accom-
panied by hydrophobic interaction and hydrogen bonds. In a more recent study, equilib-
rium dialysis was used to evaluate plasma protein binding of wogonin at diff erent concentra-
tions. The results showed elevated protein binding levels (over 90 %), which signifi cantly 
decreased the free fraction of the compound (16). Considering these data, it was concluded 
that protein binding has a distinctive role in the distribution of wogonin in plasma. Sub-
sequently, in the current procedure of standard sample preparation, specifi c approaches 
and techniques were used to optimize the simulation of in vivo conditions. These include 
the eff ects of temperature, adequate kinetic energy in addition to evasion of organic solvents 
that may interfere with protein binding. 
Finally, it was obvious that in our preliminary standard sample preparation experi-
ment drug extraction from the directly spiked standard samples (group 1) did not represent 
real extraction from the plasma matrix and such samples were regarded as incompatible 
with the test samples. In contrast, in the case when no organic solvent was included in the 
preparation of standard samples (group 2) only the drug incorporated in plasma was sub-
jected to the extraction process referring to bett er compatibility with the in vivo test sam-
ples. Then the fi nal protocol was established following the general steps in Fig. 1 (Group 2) 
using a series of 200-μL wogonin solutions in methanol (50–500 ng mL–1) and a series of 
10 μL of 30 μg mL–1 IS in methanol, all evaporated to dryness. Briefl y, plasma was allowed 
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to completely thaw at room temperature and then 200 μLwas added to each tube of the 
wogonin series. The tubes were then incubated in a shaking water bath for 20 min at 37 °C 
interspersed with 1-min vortex periods every 5 min to provide thermal conditions and 
suffi  cient mixing required to incorporate the drug under simulated in vivo conditions. It 
was then completely transferred to the series that contained IS and vortexed for 5 min. 
Addition of IS was carried out in a separate step in order to avoid any possible interference 
with the drug distribution patt ern such as competition on protein binding sites or, more 
importantly, to mimic the addition sequence of IS to the test samples and hence ensure 
higher compatibility from all aspects. This was followed by the extraction process (accord-
ing to the same protocol as with test samples) and then analysing by HPLC.
Method validation
Linearity of calibration curve. – Standard samples prepared according to the fi nal proto-
col were extracted and analysed by HPLC and were repeated to fulfi l the requirement 
recommended by the FDA bioanalytical guideline for method validation. Coeffi  cient of 
determination R2 of 0.99899 was valid throughout the linearity concentration range of 
50–500 ng mL–1, appropriate for studying wogonin pharmacokinetic behaviour in vivo. It 
is the only range in which the result of the method is trustworthy and, in addition, this 
range refl ects the real concentrations of the drug in aqueous solutions in general or plasma 
in particular.
Selectivity. – The peak of IS and wogonin eluted at 5.1 and 7.2 min, resp., with relative 
retention time RRT of 1.4. HPLC chromatograms for blank plasma, blank plasma spiked 
with wogonin and IS and test plasma from wogonin-treated rat spiked with IS are shown 
in Figs. 3a,b,c. Apparently, no interference was found at retention times of IS and wogonin, 
indicating the selectivity of the method for their separation from both standard and test 
samples, pointing to the applicability of the method for the pharmacokinetic studies of 
wogonin in vivo. 
Accuracy. – The method was shown to be accurate since the mean values of the three 
concentrations were very close to their corresponding true values, specifi cally satisfying 
the FDA recommendation of being within 15 % of the true value (12). Table I shows the 
intra- and inter-day accuracy and RSD values for each mean value of the three concentra-
tions tested.
Precision. – Precision of the method was confi rmed by the results of intra-day repeat-
ability and inter-day (intermediate) precision, which showed the closeness of individual 
measures of each concentration when the procedure was applied repeatedly. Maximum 
RSD values of 11 and 2 % for the lowest and the highest concentration, resp., which are 
within the allowed limits of the FDA regulations (15 % RSD) (12), were recorded when the 
experiment was repeated on diff erent days (Table I).
Extraction recovery. – The recorded average absolute recovery value of the current method 
was about 85 % (Table II). These results confi rm the method applicability and validity for 
the determination of wogonin from plasma within the specifi ed range.
Limit of detection and quantitation. – The method was proven to be extremely sensitive, 
with LOD of 10.5 ng mL–1 and LOQ of 31.7 ng mL–1, suggesting its suitability for bioavaila-
bility studies of oral and parenteral administration of wogonin.
381
J. M. M. Salmani et al.: Development of a new HPLC method for wogonin in rat plasma: Compatibility of standard and test samples, 
Acta Pharm. 67 (2017) 373–384.
 


















50.00 46.60 11.0 93.2  45.25 9.5 90.5
300.00 285.57   2.9 95.2 291.34 1.3 97.1
500.00 488.42   2.0 97.7 484.62 1.4 96.9
n = 5
Fig. 3. HPLC chromatograms of: a) blank plasma, b) blank plasma spiked with wogonin and api-
genin, c) plasma sample from a rat treated with wogonin aqueous suspension per os. Key to the 
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CONCLUSIONS
The current work objectifi es the weak points of previous preparations of standard 
samples such as spiking organic solvents in the plasma, illogical calibration concentration 
range and disregard of the eff ects of physicochemical properties of the drug and experi-
mental conditions. The current method also suggests applicable measures for overcoming 
these drawbacks.
Standard sample preparation during the development of an HPLC method for wogo-
nin determination in rat plasma was discussed in detail, pointing to the signifi cance of 
incompatibility between standard and test samples. It showed that method validation does 
not fulfi l its purpose and no reliable results will be achieved if wrong standards are used. 
Further, current experiments were preformed considering all factors necessary to make 
the results more valuable and trustworthy. This research highlights the importance of 
proper execution of the standard sample preparation, particularly for analytes with low 
aqueous solubility and high protein binding. To the best of our knowledge, this is the fi rst 
report emphasizing the phenomena of inappropriate implementation of standard guide-
lines in standard sample preparation that aff ect their compatibility and hence the entire 
method reliability. Due to the great importance of preventing deceptive results obtained 
if the method is validated using incompatible standard samples, this research aims to cor-
rect such drawbacks by designating the measures for achieving the required compatibility.
Further, this method was validated and was shown to be highly effi  cient and capable 
of extracting wogonin and IS (apigenin) from rat plasma accurately and precisely within 
the specifi ed range, thus suggesting its suitability for wogonin determination in plasma.
Since the incompatibility issue has not yet been considered as the primary objective of 
method development, this report could be valuable in the bioanalysis of other organic com-
pounds to avoid such problems in this early and essential step of method development.
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